Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory PCNSL Patient
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin’s lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton’s tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin’s lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton’s tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.
참고문헌 (16)
- Yuan Y, "Current and emerging therapies for primary central nervous system lymphoma", Biomark Res, 9, pp.32~ (2021)
- Schaff LR, "Primary central nervous system lymphoma", Blood, 140, pp.971~979 (2022)
- Tu S, "CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma", Front Oncol, 9, pp.1350~ (2019)
- Karschnia P, "CAR T-cells for CNS lymphoma : driving into new terrain?", Cancers(Basel), 13, pp.2503~ (2021)
- Siddiqi T, "CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma", Blood Adv, 5, pp.4059~4063 (2021)
- Qu C, "Radiation priming chimeric antigen receptor T-cell therapy in relapsed", refractory diffuse large B-cell lymphoma with high tumor burden, 2020, pp.43, 32~37
- Frigault MJ, "Safety and efficacy of tisagenlecleucel in primary CNS lymphoma : a phase 1", 2 clinical trial, 2022, pp.139, 2306~2315
- Jacobson CA, "A pilot study of axicabtagene ciloleucel(axi-cel)for the treatment of relapsed", refractory primary and secondary central nervous system lymphoma(CNSL), 2022, pp.140(Suppl 1), 1060~1061
- Tong C, "Optimized tandem CD19", CD20 CAR-engineered T cells in refractory, Blood, pp.2020, 136[DOI]
- Li T, "CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain", Front Oncol, 10, pp.1306~ (2020)
- Qu C, "Decitabine-primed tandem CD19", CD22 CAR-T therapy in relap-sed, Front Immunol, pp.2022, 13[DOI]
- Ruella M, "The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells(CART19)improves responses against mantle cell lymphoma", Clin Cancer Res, 22, pp.2684~2696 (2016)
- Sagiv-Barfi I, "Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK", Proc Natl Acad Sci U S A, 112, pp.E966~72 (2015)
- Younes A, "Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia : a phase 1", 2a study, 2019, pp.6, e67~78
- Cao Y, "Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed", refractory B-cell non-Hodgkin lymphoma, 2019, pp.9, 767~
- Zhang W, "Case report : CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma", Front Immunol, 13, pp.983934~ (2022)